Themis Bioscience

Themis Bioscience

A biotechnology company developing immune-modulation therapies for infectious diseases and cancer leveraging its technology platform and understanding of immune system mechanisms. It was founded in 2009 and is located in Vienna, Austria.

Themis Bioscience is a Vienna-based company with a focus on utilizing technology that it has developed to advance vaccine candidates for various infectious diseases. The company states that its Themaxyn platform allows for researchers to rapidly identify and develop vaccines.

COVID-19

The company worked in collaboration with the Pasteur Institute during the COVID-19 pandemic. The role of Themis Bioscience was to provide scaling and manufacturing services once its partners had developed and tested a vaccine. The time frame for when the manufacturing will take place is unknown.

Timeline

March 6, 2020

CEPI issued an urgent call for $2 billion of new funding to enable the organisation to expand the number of COVID-19 vaccine candidates in development and to fund the clinical trials for these candidate vaccines.

CEPI, the Coalition for Epidemic Preparedness Innovations, today added an eighth COVID-19 vaccine candidate to its portfolio. CEPI will invest an initial US$4.9 million in a partnering agreement with the Institut Pasteur-led consortium that will include Themis and the University of Pittsburgh to develop a vaccine candidate against COVID-19.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Themis Bioscience funding round, September 2019
Series D round
44,000,000
September 2019
Hadean Ventures
Themis funding round, January 2018
Series C round
12,000,000
January 2018
Global Health Investment Fund
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dr. Erich Tauber

CEO, Co-Founder

Further reading

Title
Author
Link
Type
Date

Austrian Vaccine Developer Signs Deal with MSD in 'Blockbuster Indication'

Clara Rodriguez Fernandez

Web

August 22, 2019

Themis and Institut Pasteur Join Coronavirus Vaccine Hunt

Web

March 20, 2020

Documentaries, videos and podcasts

Title
Date
Link

BIO-Europe Spring 2019: Themis Bioscience Harnesses Measles Vector For Immune Modulation

May 22, 2019

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.